RxDoctor Payments Data

Lesa Beach, NP

Family · Albany, GANPI 1831442888

Payments from drug & device makers

$4,510in general payments, 2019–2025

Across 221 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$979
  • Johnson & Johnson$576
  • Indivior Inc.$562
  • Alkermes, Inc.$544
  • Teva Pharmaceuticals USA, Inc.$536
  • E.r. Squibb & Sons, L.L.C.$485
  • plus $828 from 6 others

What the payments were for

  • Food & beverage$4,35997%
  • Education$1513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,510 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$9,329
Medicare patients
58
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate89$255,883
Risperdal ConstaRisperidone Microspheres86$92,875
Abilify MaintenaAripiprazole14$40,613
VraylarCariprazine Hcl24$38,525
Aripiprazole47$7,641
Benztropine Mesylate432$5,342
Paliperidone ErPaliperidone17$4,195
Haloperidol Decanoate92$3,994
Clozapine41$3,815
Quetiapine Fumarate226$3,097
Fluphenazine Decanoate30$2,812
Risperidone247$2,554
Fluphenazine Hcl24$2,401
Olanzapine184$2,190
Trazodone Hcl199$1,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$576$348,758175 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$181$40,61314 claims
AbbVieVraylar$979$38,52524 claims
Teva Pharmaceuticals USA, Inc.Loxapine$536$74724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →